Merck (MRK) Other Non-Current Assets (2009 - 2026)
Merck (MRK) reported Other Non-Current Assets of $19.8 billion for Q1 2026, up 18.12% year-over-year from $16.8 billion in Q1 2025, and up 5.25% on a QoQ basis from $18.8 billion in Q4 2025.
Merck (MRK) has 16 years of Other Non-Current Assets data on file, last reported at $19.8 billion in Q1 2026.
- Quarterly Other Non-Current Assets rose 18.12% year-over-year to $19.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.8 billion (up 18.12% YoY) and the FY2025 annual result came in at $18.8 billion, up 17.29% from the prior year.
- Other Non-Current Assets advanced to $19.8 billion in Q1 2026 per MRK's latest filing, from $18.8 billion in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $19.8 billion in Q1 2026 and bottomed at $4.0 million in Q2 2022.
- The 5-year median for Other Non-Current Assets is $13.6 billion (2024), against an average of $12.8 billion.
- The widest annual swing landed in 2024, when Other Non-Current Assets surged 18308.7%; it then advanced 17.29% in 2025.
- Tracing MRK's Other Non-Current Assets over 5 years: stood at $9.5 billion in 2022, then grew by 25.9% to $12.0 billion in 2023, then soared by 33.74% to $16.0 billion in 2024, then increased by 17.29% to $18.8 billion in 2025, then climbed by 5.25% to $19.8 billion in 2026.
- Per Business Quant, the three latest MRK Other Non-Current Assets figures stand at $19.8 billion (Q1 2026), $18.8 billion (Q4 2025), and $18.3 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 200.00 Mn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 7.23 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 14.11 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 10.54 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 19.81 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 12.76 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 4.55 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 9.83 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 6.08 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 2.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.81 Bn |
| Dec 31, 2025 | 18.82 Bn |
| Sep 30, 2025 | 18.33 Bn |
| Jun 30, 2025 | 17.66 Bn |
| Mar 31, 2025 | 16.77 Bn |
| Dec 31, 2024 | 16.04 Bn |
| Sep 30, 2024 | 14.44 Bn |
| Jun 30, 2024 | 12.70 Bn |
| Mar 31, 2024 | 12.33 Bn |
| Dec 31, 2023 | 12.00 Bn |
| Sep 30, 2023 | 10.56 Bn |
| Jun 30, 2023 | 69.00 Mn |
| Dec 31, 2022 | 9.53 Bn |
| Jun 30, 2022 | 4.00 Mn |
| Mar 31, 2021 | 1.05 Bn |
| Dec 31, 2020 | 2.68 Bn |
| Sep 30, 2020 | 74.00 Mn |
| Jun 30, 2020 | 74.00 Mn |
| Dec 31, 2019 | 60.00 Mn |
| Jun 30, 2019 | 4.00 Mn |
| Dec 31, 2018 | 106.00 Mn |
| Sep 30, 2018 | 253.00 Mn |
| Jun 30, 2018 | 211.00 Mn |
| Dec 31, 2017 | 66.00 Mn |
| Jun 30, 2016 | 533.00 Mn |
| Sep 30, 2014 | 3.30 Bn |
| Jun 30, 2014 | 3.38 Bn |
| Mar 31, 2014 | 3.22 Bn |
| Dec 31, 2013 | 26.00 Mn |
| Mar 31, 2011 | 5.81 Bn |
| Dec 31, 2010 | 5.63 Bn |
| Sep 30, 2010 | 5.40 Bn |
| Jun 30, 2010 | 5.03 Bn |
| Mar 31, 2010 | 5.53 Bn |
| Dec 31, 2009 | 5.38 Bn |
| Sep 30, 2009 | 1.60 Bn |
| Jun 30, 2009 | 1.25 Bn |